drugset / Trial / NCT07335887
Sonrotoclax Plus Dexamethasone With or Without Daratumumab Regimen in Patients With t(11;14) Primary AL Amyloidosis
NaSingle-groupOpen-labelTreatment
Summary
The goal of this study is to evaluate the efficacy and safety of Sonrotoclax combined Regimen in patients with t(11;14) AL amyloidosis. Participants will receive the Sonrotoclax Plus Dexamethasone regimen with or without Daratumumab for 12 cycles. The Hematologic Response, Organ Response, Survival, and Safety will be evaluated.
Timeline
- Start
- 2026-01-01
- Primary completion
- 2028-02-29
- Completion
- 2029-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Daratumumab | Monoclonal antibody | 16 mg/kg | Intravenous |
| Subject | Daratumumab | Monoclonal antibody | 1800 mg | Intravenous |
| Subject | Dexamethasone | Small molecule | 40 mg | — |
| Subject | Sonrotoclax | Other / unclassified | — | — |